Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00833
|
|||||
| Drug Name |
Naringenin
|
|||||
| Synonyms |
( inverted exclamation markA)-Naringenin; (+/-)-Naringenin; (-)-Naringenin; (S)-Naringenin; 4',5,7-Trihydroxyflavanone; 4',7-Trihydroxyflavanone; 480-41-1; 5,7,4'-Trihydroxyflavanone; 5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 67604-48-2; 93602-28-9; AK122638; BE-14348A; CHEBI:50202; CHEMBL32571; FTVWIRXFELQLPI-UHFFFAOYSA-N; Flavanone, 4',5,7-trihydroxy-; MFCD00006844; MLS000028739; MLS000738094; NARIGENIN; NSC 11855; NSC 34875; NSC11855; NSC34875; Naringenine; SMR000059039; Salipurol; naringenin; naringetol; salipurpol
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Phase 1 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H12O5
|
|||||
| Canonical SMILES |
C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O
|
|||||
| InChI |
InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2
|
|||||
| InChIKey |
FTVWIRXFELQLPI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 480-41-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 272.25 | Topological Polar Surface Area | 87 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
2.4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:50202
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01091077) A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection | |||||
| 2 | Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.